Esperion Therapeutics (ESPR) Leases (2019 - 2025)
Historic Leases for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $3.3 million.
- Esperion Therapeutics' Leases fell 4656.06% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 4656.06%. This contributed to the annual value of $5.5 million for FY2024, which is 1792.51% up from last year.
- Esperion Therapeutics' Leases amounted to $3.3 million in Q3 2025, which was down 4656.06% from $4.2 million recorded in Q2 2025.
- Esperion Therapeutics' 5-year Leases high stood at $7.1 million for Q1 2024, and its period low was $730000.0 during Q3 2022.
- Over the past 5 years, Esperion Therapeutics' median Leases value was $3.7 million (recorded in 2021), while the average stood at $3.6 million.
- As far as peak fluctuations go, Esperion Therapeutics' Leases crashed by 8034.99% in 2022, and later skyrocketed by 56325.58% in 2024.
- Over the past 5 years, Esperion Therapeutics' Leases (Quarter) stood at $1.9 million in 2021, then plummeted by 45.42% to $1.0 million in 2022, then soared by 351.25% to $4.7 million in 2023, then increased by 17.93% to $5.5 million in 2024, then plummeted by 39.69% to $3.3 million in 2025.
- Its Leases stands at $3.3 million for Q3 2025, versus $4.2 million for Q2 2025 and $5.0 million for Q1 2025.